A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-11

Study Completion Date

2017-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A single-center, prospective, non-randomized, clinical and first-in-human study. Each patient will be studied during a single treatment session of ten hours. The device will be connected to an existing, standard PD catheter that the patient will be using routinely prior to the study (i.e. a peritoneal dialysis catheter will not be specifically inserted for the study). The patient will be hospitalized for observation during the test day and during the night following the study session. Ultrafiltration volume, dialysate glucose concentrations, blood glucose concentrations as well the patient's acceptability and tolerance of the wearable device will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Feasibility Study of Peritoneal Ultrafiltration With a Wearable Device, CLS UF, That Adds a Glucose-salt Solution to the Intraperitoneal Fluid in the Device, in Order to Maintain a Stable Intraperitoneal Osmolarity and Thereby Enhance Ultrafiltration.

NCT03128073

Ultrafiltration Failure

COMPLETED NA

Carry Life@ UF System Clinical Study

NCT05874804

End Stage Renal Disease

COMPLETED NA

A Performance Analysis of the Peritoneal Ultrafiltration (PUF) Achieved With the Carry Life® UF

NCT03724682

Chronic Renal Failure

COMPLETED NA

Primary Clinical Evaluation of Wearable Filtrating Artificial Kidney Device for On-site Medical Rescue

NCT05906355

Fluid Overload

NOT_YET_RECRUITING NA

Influence of Variable Inflow Volume, Dwell Duration and Glucose Concentration on Ultrafiltration Volume in APD Patients

NCT06443021

Renal Failure Chronic Kidney Diseases

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Cardio-Renal Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Device: CLS UF

The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.

Group Type EXPERIMENTAL

CLS UF

Intervention Type DEVICE

One single ultrafiltration session of 10 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CLS UF

One single ultrafiltration session of 10 hours.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Carry LifeTM System Ultra Filtration

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient, 18-80 years of age.
* Prevalent PD patients with CHF with cardio-renal syndrome type II, on stable ultrafiltration, for more than two months, treated with PD based UF according to German national guidelines.

* Therapy resistance of pharmacologic therapy: resistant hypervolemia with ascites, pleural fluid and pulmonary edema
* Recurrent hospitalization with cardiac decompensation, ≥ 2 occasions during the last six months
* Isolated failure of the right heart chamber
* Treatment based on night time APD therapy combined with a day time long dwell.
* Obtained written consent to participate in the study.

Exclusion Criteria

* End stage renal disease requiring dialysis.
* Malignant disease.
* On-going infection.
* Diabetes mellitus.
* HIV and/or hepatitis positive.
* Pregnancy.
* Breastfeeding women.
* Participation in other clinical trials within one month before inclusion.
* Abdominal hernia.
* Cardiac diseases other than left ventricular heart failure, biventricular heart failure or isolated right heart chamber failure, with volume overload.
* Any immune deficiency.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No